
NOMA AI is a medtech company developing a real-time AI platform that integrates multimodal clinical data and advanced AI to provide predictive patient monitoring and risk assessment solutions. Their initial focus is on maternal hemorrhage, the leading cause of maternal mortality and morbidity globally and in the U.S. The platform integrates with hospital IT and electronic health record systems to deliver real-time risk predictions and clinical decision support, enabling proactive interventions to prevent complications. NOMA AI's solution addresses the unmet need for accurate early risk assessment and detection of maternal hemorrhage, improving clinical workflows and patient outcomes. The company collaborates with clinical experts to expand its portfolio of life-saving AI-driven healthcare solutions.

NOMA AI is a medtech company developing a real-time AI platform that integrates multimodal clinical data and advanced AI to provide predictive patient monitoring and risk assessment solutions. Their initial focus is on maternal hemorrhage, the leading cause of maternal mortality and morbidity globally and in the U.S. The platform integrates with hospital IT and electronic health record systems to deliver real-time risk predictions and clinical decision support, enabling proactive interventions to prevent complications. NOMA AI's solution addresses the unmet need for accurate early risk assessment and detection of maternal hemorrhage, improving clinical workflows and patient outcomes. The company collaborates with clinical experts to expand its portfolio of life-saving AI-driven healthcare solutions.
Sector: Medtech — real-time AI for clinical monitoring
Initial focus: Maternal hemorrhage risk assessment and detection
Headquarters: Pittsburgh, PA
Team size (reported): 8 employees
Reported funding: USD 1,100,000 (total reported)
Predictive patient monitoring and clinical decision support for acute obstetric complications (maternal hemorrhage prioritized).
Medical technology / Healthcare AI
Crunchbase lists a pre-seed round led by Cedars-Sinai Accelerator; public profile obfuscates some funding details.